Navigation Links
Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
Date:6/21/2013

JERUSALEM, June 21, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will be presenting its abstract titled, "Dose response to oral insulin capsules in fasting, healthy subjects," at the 73rd Scientific Sessions of the American Diabetes Association, on June 21st through 25th, 2013, in Chicago, Illinois, USA.

The abstract will be on display on Sunday, June 23rd, from 12:00-2:00pm, and attended by Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

The abstract has also been selected for showcase in the Scientific Session's Innovative Oral Agents - Innovative Discoveries Guided Audio Poster Tour, to be held on Monday, June 24, 2013. This 50-min tour presents and provides a moderated discussion of 7 to 8 posters that expose meeting attendees to particularly novel or recent developments in the field.

The American Diabetes Association (ADA) Scientific Sessions' five-day meeting features advances in the prevention, diagnosis, and treatment of diabetes. The program is organized into eight distinctive theme areas and includes presentations by diabetes experts.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 c
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Announces Withdrawal of Proposed Underwritten Public Offering
2. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
3. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
4. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
5. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
6. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
7. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
8. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
9. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
10. Oramed Submits New IND Application for Oral Insulin Trial in the US
11. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... Aug. 29, 2014  A Boston Scientific Corporation ... on stent removability and preliminary long term stricture ... in the August issue of the peer-reviewed journal, ... is being conducted in 11 countries and ... self-expanding metal stents (FCSEMS) after extended indwell (i.e., ...
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... May 20 The owner and operator of a Houston-area ... program, announced the Departments of Justice and Health and Human Services (HHS). ... William M. ... fraud before U.S. District Judge David Hittner in U.S. District ...
... May 20 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of rapid ... Citi Global Health Care Conference being held May 26 through ... New York City .  Jon Russell, Vice President, Finance, will attend. ...
Cached Medicine Technology:Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 2Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 3
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment ... markets (the US, France, Italy, Germany, Spain and the ... by 2018. , The competitive landscape in the B-cell ... and the UK is poised to undergo a dramatic ... four largest B-cell NHL indications, which includes Diffuse Large ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... Nov. 29 Boston Scientific,Corporation (NYSE: BSX ... Food,and Drug Administration (FDA) advisory panel to approve ... stent system. The,PROMUS and XIENCE V stent systems ... Abbott in international markets. Both stent,systems would be ...
... 29 "CT scans are helping to,save countless ... disorders. Indeed, the New England Journal of Medicine ... one of the top 11,innovations of the past ... that detect and treat life threatening diseases CT,scans ...
... International Website goes beyond, Typical ,Best, and ... Affecting ... Determining health risks and the,quality of medical care ... published MEDEX 360m International Healthcare Rating,System, high standards of ...
... November 29 Bavarian Nordic,reports the successful completion ... healthy subjects who received either one or two ... of this,study are seen as the pivotal step ... registration trials in order to achieve a BLA ...
... genetics appear to be key factors, researchers say , , ... -- over and above socio-economic factors -- appear to ... breast cancer, U.S. researchers are reporting. , One new ... cancer patients and their white counterparts, indicating that cancer ...
... by a University of Pennsylvania biologist in the tick-infested woods ... that mice are the main animal reservoir for Lyme disease ... Proceedings of the Royal Society B, demonstrates that chipmunks and ... that account for major outbreaks. , According to the study, white-footed ...
Cached Medicine News:Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Statement by MITA Vice President Andrew Whitman on the Benefits of CT Scans Relative to Radiation Dose Risks 2Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate 2Health News:Studies Reveal Why Breast Cancer Hits Black Women Harder 2Health News:Studies Reveal Why Breast Cancer Hits Black Women Harder 3Health News:University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 2
Toxoplasma IgG II ELISA...
ELISA kit for CMV CAP M....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Medicine Products: